Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors July 28, 2026
Lupin spins out two oncology programs LNP7457 (PRMT5) and LNP8701 (SOS1) into Kaveri Therapeutics July 28, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
Enrollment completed in Ph 1 Dose Escalation Study of IPH4502 in patients with advanced solid tumors July 28, 2026
Confirmed Durable Partial Response in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy July 28, 2026
First Patient Dosed in Ph 1 Trial of IM-3050 in Patients with FAP-Expressing Advanced Solid Tumors July 22, 2026
Ph 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors published in the JCO July 21, 2026
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors July 21, 2026
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development July 15, 2026
FDA Accepts NDA for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma; PDUFA: May 2027 July 15, 2026
Updated Preliminary Ph 1 Data and Registration-Enabling Plans for ERAS-0015 in KRAS-Mutant Solid Tumors Announced July 15, 2026
FDA Clears IND Application for LTZ-232 to Treat Advanced Metastatic CRC and Other Solid Tumors July 15, 2026
Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3‑Expressing Solid Tumors July 7, 2026
Positive Interim Ph 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability of PAS-004, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Announced July 7, 2026
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies June 30, 2026
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Ph 1/2 Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors June 30, 2026
Enhertu approved in the EU for patients with previously treated HER2+ve metastatic solid tumours June 30, 2026
